Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2010 April;51(2) > The Journal of Cardiovascular Surgery 2010 April;51(2):203-12

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

ORIGINAL ARTICLES  ADVANCES IN BELOW KNEE ENDOVASCULAR INTERVENTIONS


The Journal of Cardiovascular Surgery 2010 April;51(2):203-12

lingua: Inglese

Drug eluting stents versus PTA with GP IIb/IIIa blockade below the knee in patients with current ulcers. The BELOW Study

Tepe G., Schmehl J., Heller S., Brechtel K., Heuschmid M., Fenchel M., Kramer U., Miller S., Claussen C. D.

1 Institute for Diagnostic and Interventional Radiology Hospital of Rosenheim, Rosenheim, Germany;
2 Department of Diagnostic Radiology, University of Tuebingen, Tuebingen, Germany


PDF  


The study was designed as a feasibility trial to evaluate the use of GP IIb/IIIa blockade in connection with drug eluting stents, bare stents and PTA only. Sixty patients with current ulcers were randomly assigned to receive abciximab plus a Sirolimus coated stent (N.=14), abciximab plus a bare stent (N.=16), abciximab plus PTA (N.=14) and PTA alone (N.=19). Angiographic control was performed at two and six months. Recanalization was successful in all cases. Two month restenosis rate was 9%, 45.5%, 67% and 46%. At six month follow-up restenosis rate was 9%, 67%, 75% and 58%, respectively; 14% of all patients had major amputations within six months. Adjunctive administration of abciximab during peripheral arterial intervention below the knee was found to be safe. Sirolimus coated stent administration was followed by a higher patency rate.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

gunnar.tepe@kliro.de